S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Urgent Warning (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Urgent Warning (Ad)
Closing prices for crude oil, gold and other commodities
The Bottom Is In For Accenture
Modern Day Options Trading For Beginners! (Ad)pixel
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Urgent Warning (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Urgent Warning (Ad)
Closing prices for crude oil, gold and other commodities
The Bottom Is In For Accenture
Modern Day Options Trading For Beginners! (Ad)pixel
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Urgent Warning (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Urgent Warning (Ad)
Closing prices for crude oil, gold and other commodities
The Bottom Is In For Accenture
Modern Day Options Trading For Beginners! (Ad)pixel
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
Urgent Warning (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
Urgent Warning (Ad)
Closing prices for crude oil, gold and other commodities
The Bottom Is In For Accenture
Modern Day Options Trading For Beginners! (Ad)pixel
14 Best Consumer Staples Dividend Stocks
10 Best Consumer Discretionary ETFs
NYSE:BHC

Bausch Health Companies - BHC Stock Forecast, Price & News

$7.23
-0.05 (-0.69%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.02
$7.25
50-Day Range
$7.16
$9.85
52-Week Range
$4.00
$23.97
Volume
4.42 million shs
Average Volume
4.81 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.60

Bausch Health Companies MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
46.6% Upside
$10.60 Price Target
Short Interest
Bearish
7.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$2,721 Sold Last Quarter
Proj. Earnings Growth
10.59%
From $3.21 to $3.55 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

237th out of 989 stocks

Pharmaceutical Preparations Industry

99th out of 480 stocks


BHC stock logo

About Bausch Health Companies (NYSE:BHC) Stock

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
RBC Capital Reaffirms Their Hold Rating on Bausch Health Companies (BHC)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
BHC.TO - | Stock Price & Latest News | Reuters
See More Headlines
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Company Calendar

Last Earnings
8/02/2021
Today
3/25/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.60
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+46.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-225,000,000.00
Pretax Margin
-1.59%

Debt

Sales & Book Value

Annual Sales
$8.12 billion
Cash Flow
$6.57 per share
Book Value
$0.72 per share

Miscellaneous

Free Float
312,111,000
Market Cap
$2.62 billion
Optionable
Optionable
Beta
1.00

Key Executives

  • Thomas J. Appio
    Chief Executive Officer & Director
  • Mirza Dautbegovic
    Chief Operating Officer & Senior Vice President
  • Tom G. Vadaketh
    Chief Financial Officer & Executive Vice President
  • Tage Ramakrishna
    Chief Medical Officer, President-R&D
  • Seana-Lyn Carson
    Executive Vice President & General Counsel













BHC Stock - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings
or view top-rated stocks.

What is Bausch Health Companies' stock price forecast for 2023?

4 analysts have issued twelve-month price targets for Bausch Health Companies' stock. Their BHC share price forecasts range from $6.00 to $15.00. On average, they anticipate the company's share price to reach $10.60 in the next year. This suggests a possible upside of 46.6% from the stock's current price.
View analysts price targets for BHC
or view top-rated stocks among Wall Street analysts.

How have BHC shares performed in 2023?

Bausch Health Companies' stock was trading at $6.28 at the beginning of the year. Since then, BHC stock has increased by 15.1% and is now trading at $7.23.
View the best growth stocks for 2023 here
.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest in February. As of February 28th, there was short interest totaling 27,480,000 shares, an increase of 15.8% from the February 13th total of 23,740,000 shares. Based on an average trading volume of 5,710,000 shares, the short-interest ratio is presently 4.8 days. Approximately 7.7% of the shares of the stock are short sold.
View Bausch Health Companies' Short Interest
.

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our BHC earnings forecast
.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) issued its earnings results on Monday, August, 2nd. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.02. The business earned $2.10 billion during the quarter, compared to the consensus estimate of $2.12 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 553.04% and a negative net margin of 2.77%.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.45 billion-$4.60 billion, compared to the consensus revenue estimate of $8.31 billion.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Goldentree Asset Management LP (5.88%), Franklin Resources Inc. (4.89%), Natixis (4.37%), National Bank of Canada FI (3.63%), Laurion Capital Management LP (2.88%) and Lombard Odier Asset Management USA Corp (0.00%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Holdings LP Valueact, John Paulson, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson, Steven D Miller and William D Humphries.
View institutional ownership trends
.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $7.23.

How much money does Bausch Health Companies make?

Bausch Health Companies (NYSE:BHC) has a market capitalization of $2.62 billion and generates $8.12 billion in revenue each year. The company earns $-225,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How many employees does Bausch Health Companies have?

The company employs 19,900 workers across the globe.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The official website for the company is www.bauschhealth.com. The company can be reached via phone at (514) 744-6792, via email at ir@bauschhealth.com, or via fax at 514-744-6272.

This page (NYSE:BHC) was last updated on 3/25/2023 by MarketBeat.com Staff